Man in violation of privacy law

Breaking news and expert analysis on legal and compliance issues

[Back To Home][Back To Archives]

From Antitrust Law Daily, June 24, 2013

U.S. Supreme Court vacates Third Circuit decision establishing presumption of illegality for reverse payment agreements

By Jeffrey May, J.D.

Today, the U.S. Supreme Court, in light of its recent decision in FTC v Actavis, Inc., vacated a decision of the U.S. Court of Appeals in Philadelphia (2012-2 Trade Cases ¶77,971), calling for the application of a “quick look” approach for analyzing “reverse payment agreements,” in which patent holders pay a generic manufacturer to drop its patent challenge and refrain from entering the market for a specified period of time. In Actavis (2013-1 Trade Cases ¶78,432), the Supreme Court held that such agreements were subject to full rule of reason analysis, despite the FTC's argument that a quick-look presumption was appropriate (Merck & Co. v. Louisiana Wholesale Drug Co., No. 12-245; Upsher-Smith Laboratories, Inc. v. Louisiana Wholesale Drug Co., 12-265).

In order to vacate the decision, the Supreme Court granted two petitions for review. Brand-name drug maker Merck & Co. had filed a petition for review on August 24, 2012, and generic drug maker Upsher-Smith Laboratories Inc. had filed a similar petition on August 28, 2012. Justice Samuel Alito took no part in the consideration or decision of these petitions.

In K-Dur Antitrust Litigation, the U.S. Court of Appeals in Philadelphia ruled that reverse payment settlements between patent holders and would-be generic competitors in the pharmaceutical industry should be reviewed under a “quick look” rule of reason analysis based on the economic realities of the reverse payment settlement. This is one of the appellate court decisions that helped to create a split among the circuits on the appropriate standard for review of these agreement, thereby prompting U.S. Supreme Court review in Actavis.

Reversing summary judgment in favor of the drug companies, the Third Circuit held that wholesalers and retailers who purchased a brand-name sustained-release potassium chloride supplement (K-Dur) used to treat high blood pressure could proceed with an antitrust challenge to patent infringement litigation settlement agreements between Schering-Plough Corporation—the manufacturer of K-Dur—and generic drug companies. The purchasers alleged that the settlements included payments from Schering to the generic drug makers and resulted in the delayed entry of a generic alternative to K-Dur.

Attorneys: Kannon K. Shanmugam (Williams & Connolly LLP) for Merck & Co. Thomas C. Goldstein (Goldstein & Russell, P.C.) for Louisiana Wholesale Drug Company, Inc. Jay P. Lefkowitz (Kirkland & Ellis LLP) for Upsher-Smith Laboratories, Inc.

Companies: Merck & Co.; Louisiana Wholesale Drug Company, Inc.; Upsher-Smith Laboratories, Inc.; Schering-Plough Corp.

MainStory: TopStory Antitrust

Antitrust Law Daily

Introducing Wolters Kluwer Antitrust Law Daily — a daily reporting service created by attorneys, for attorneys — providing same-day coverage of breaking news, court decisions, legislation, and regulatory activity.

A complete daily report of the news that affects your world

  • View full summaries of federal and state court decisions.
  • Access full text of legislative and regulatory developments.
  • Customize your daily email by topic and/or jurisdiction.
  • Search archives for stories of interest.

Not just news — the right news

  • Get expert analysis written by subject matter specialists—created by attorneys for attorneys.
  • Track law firms and organizations in the headlines with our new “Who’s in the News” feature.
  • Promote your firm with our new reprint policy.

24/7 access for a 24/7 world

  • Forward information with special copyright permissions, encouraging collaboration between counsel and colleagues.
  • Save time with mobile apps for your BlackBerry, iPhone, iPad, Android, or Kindle.
  • Access all links from any mobile device without being prompted for user name and password.